| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Yusuf Aydın, Hülya Coşkun, Seher Kır, Selma Yazici, Özlem Kudaş, Adem Güngö. Rheumatoid arthritis masquerading as acromegaly recurrence: report of two cases. Rheumatology international. vol 32. issue 9. 2013-03-01. PMID:20369240. |
acromegaly is a chronic endocrinopathy characterized by hypersecretion of growth hormone (gh) and consequently of insulin-like growth factor-1 (igf-1). |
2013-03-01 |
2023-08-12 |
Not clear |
| Yusuf Aydın, Hülya Coşkun, Seher Kır, Selma Yazici, Özlem Kudaş, Adem Güngö. Rheumatoid arthritis masquerading as acromegaly recurrence: report of two cases. Rheumatology international. vol 32. issue 9. 2013-03-01. PMID:20369240. |
after excluding the acromegaly activation and arthropathy by gh and igf-1 measurement, according to clinical presentation, laboratory and radiological assessments, patients were diagnosed as ra. |
2013-03-01 |
2023-08-12 |
Not clear |
| Antônio Ribeiro-Oliveira, Ariel Barka. The changing face of acromegaly--advances in diagnosis and treatment. Nature reviews. Endocrinology. vol 8. issue 10. 2013-02-06. PMID:22733271. |
acromegaly is a chronic disease characterized by the presence of a pituitary growth hormone (gh)-producing tumour, excessive secretion of growth hormone, raised levels of insulin-like growth factor i (igf-i) and characteristic clinical presentation of acral enlargement. |
2013-02-06 |
2023-08-12 |
Not clear |
| Antônio Ribeiro-Oliveira, Ariel Barka. The changing face of acromegaly--advances in diagnosis and treatment. Nature reviews. Endocrinology. vol 8. issue 10. 2013-02-06. PMID:22733271. |
over the past two decades, major advances have occurred in the understanding of some aspects of acromegaly--such as the biology of pituitary tumours, the physiology, molecular mechanisms of gh secretion and igf-i generation, and the pathogenesis of comorbidities. |
2013-02-06 |
2023-08-12 |
Not clear |
| L Boero, M Manavela, T Meroño, P Maidana, L Gómez Rosso, F Brite. GH levels and insulin sensitivity are differently associated with biomarkers of cardiovascular disease in active acromegaly. Clinical endocrinology. vol 77. issue 4. 2013-02-04. PMID:22510144. |
gh levels and insulin sensitivity are differently associated with biomarkers of cardiovascular disease in active acromegaly. |
2013-02-04 |
2023-08-12 |
Not clear |
| L Boero, M Manavela, T Meroño, P Maidana, L Gómez Rosso, F Brite. GH levels and insulin sensitivity are differently associated with biomarkers of cardiovascular disease in active acromegaly. Clinical endocrinology. vol 77. issue 4. 2013-02-04. PMID:22510144. |
acromegaly is characterized by gh excess and insulin resistance. |
2013-02-04 |
2023-08-12 |
Not clear |
| David D W Kim, Jovina Goh, Zaven Panossian, Greg Gamble, Ian Holdaway, Andrew Gre. Pioglitazone in acromegaly - an open-label, prospective study. Clinical endocrinology. vol 77. issue 4. 2013-02-04. PMID:22512403. |
preclinical studies demonstrate that thiazolidinediones (tzds) decrease growth hormone (gh) and insulin-like growth factor-1 (igf-1) levels, suggesting that they might be effective treatments for acromegaly. |
2013-02-04 |
2023-08-12 |
Not clear |
| Renata S Auriemma, Rosario Pivonello, Maria Cristina De Martino, Giuseppe Cudemo, Ludovica F S Grasso, Mariano Galdiero, Ylenia Perone, Annamaria Cola. Treatment with GH receptor antagonist in acromegaly: effect on cardiac arrhythmias. European journal of endocrinology. vol 168. issue 1. 2013-02-04. PMID:23065994. |
treatment with gh receptor antagonist in acromegaly: effect on cardiac arrhythmias. |
2013-02-04 |
2023-08-12 |
Not clear |
| Claudia Giavoli, Eriselda Profka, Elisa Verrua, Cristina L Ronchi, Emanuele Ferrante, Silvia Bergamaschi, Elisa Sala, Elena Malchiodi, Andrea G Lania, Maura Arosio, Bruno Ambrosi, Anna Spada, Paolo Beck-Pecco. GH replacement improves quality of life and metabolic parameters in cured acromegalic patients with growth hormone deficiency. The Journal of clinical endocrinology and metabolism. vol 97. issue 11. 2013-01-25. PMID:22904173. |
effects of gh replacement in patients with gh deficiency (ghd) after a cure for acromegaly so far have been poorly studied, although its prevalence among acromegalic patients may reach the 60%. |
2013-01-25 |
2023-08-12 |
Not clear |
| Claudia Giavoli, Eriselda Profka, Elisa Verrua, Cristina L Ronchi, Emanuele Ferrante, Silvia Bergamaschi, Elisa Sala, Elena Malchiodi, Andrea G Lania, Maura Arosio, Bruno Ambrosi, Anna Spada, Paolo Beck-Pecco. GH replacement improves quality of life and metabolic parameters in cured acromegalic patients with growth hormone deficiency. The Journal of clinical endocrinology and metabolism. vol 97. issue 11. 2013-01-25. PMID:22904173. |
the aim of the study was to evaluate whether metabolic parameters and quality of life are improved by gh replacement in patients with prior acromegaly and severe ghd. |
2013-01-25 |
2023-08-12 |
Not clear |
| E Lin, T L Wexler, L Nachtigall, N Tritos, B Swearingen, L Hemphill, J Loeffler, B M K Biller, A Klibanski, K K Mille. Effects of growth hormone deficiency on body composition and biomarkers of cardiovascular risk after definitive therapy for acromegaly. Clinical endocrinology. vol 77. issue 3. 2013-01-17. PMID:22315983. |
however, the effects of developing gh deficiency after definitive treatment of acromegaly are largely unknown. |
2013-01-17 |
2023-08-12 |
Not clear |
| Nicholas F Marko, Emily LaSota, Amir H Hamrahian, Robert J Wei. Comparative effectiveness review of treatment options for pituitary microadenomas in acromegaly. Journal of neurosurgery. vol 117. issue 3. 2013-01-01. PMID:22725987. |
acromegaly, a syndrome of excess growth hormone (gh) secretion typically caused by a gh-secreting pituitary adenoma, reduces life expectancy by approximately 10 years when left untreated. |
2013-01-01 |
2023-08-12 |
Not clear |
| S N Boysan, F Kantarci, O Celik, I Mihmanli, N Gazioglu, Pinar Kadiogl. Atherosclerotic risk factors and premature atherosclerosis in acromegaly before and after 48 months of octreotide-LAR treatment. Angiology. vol 63. issue 7. 2012-11-19. PMID:22238353. |
in conclusion, premature atherosclerosis was demonstrated in active acromegaly patients probably as a consequence of insulin resistance and direct vascular effects of gh and/or insulin-like growth factor 1. |
2012-11-19 |
2023-08-12 |
Not clear |
| Emmanuel Somm, Nicolas Bonnet, Alberto Martinez, Philip M H Marks, Verity A Cadd, Mark Elliott, Audrey Toulotte, Serge L Ferrari, René Rizzoli, Petra S Hüppi, Elaine Harper, Shlomo Melmed, Richard Jones, Michel L Auber. A botulinum toxin-derived targeted secretion inhibitor downregulates the GH/IGF1 axis. The Journal of clinical investigation. vol 122. issue 9. 2012-11-19. PMID:22850878. |
we designed and tested a bont-derived targeted secretion inhibitor (tsi) targeting pituitary somatotroph cells to suppress growth hormone (gh) secretion and treat acromegaly. |
2012-11-19 |
2023-08-12 |
rat |
| Hideyuki Arita, Manabu Kinoshita, Satoru Oshino, Tetsuhiro Kitamura, Michio Otsuki, Soji Kasayama, Toshio Shimokawa, Iichiro Shimomura, Toshiki Yoshimine, Youichi Saito. Biological characteristics of growth hormone-producing pituitary adenomas are different according to responsiveness to thyrotropin-releasing hormone. The Journal of clinical endocrinology and metabolism. vol 97. issue 8. 2012-10-24. PMID:22569237. |
the paradoxical response of gh to trh in patients with acromegaly has been previously reported. |
2012-10-24 |
2023-08-12 |
Not clear |
| Nilanjan Sengupta, Uma Sinha, Keshab Sinha Roy, Sudipta Sah. Acromegaly without acral changes: A rare presentation. Indian journal of endocrinology and metabolism. vol 16. issue 3. 2012-10-02. PMID:22629521. |
acromegaly was proven by high level of serum insulin like growth factor-1 (igf-1) and elevated and nonsuppressed level of growth hormone (gh), with other hormonal profile being undisturbed. |
2012-10-02 |
2023-08-12 |
Not clear |
| Zdenko Killinger, Martin Kužma, Lenka Sterančáková, Juraj Paye. Osteoarticular changes in acromegaly. International journal of endocrinology. vol 2012. 2012-09-26. PMID:23008710. |
acromegaly is caused by hypersecretion of growth hormone (gh) and consequently of insulin-like growth factor-i (igf-1) due to pituitary tumor. |
2012-09-26 |
2023-08-12 |
Not clear |
| Pinaki Dutta, Anil Bhansali, Kim Vaiphei, Usha Dutta, P Ravi Kumar, Shariq Masoodi, Kanchan Kumar Mukherjee, Alka Varma, R Kochha. Colonic neoplasia in acromegaly: increased proliferation or deceased apoptosis? Pituitary. vol 15. issue 2. 2012-09-21. PMID:21451936. |
we aimed to evaluate the proliferative and apoptotic markers in samples of colonic mucosa obtained during screening colonoscopic biopsy from patients with acromegaly and study their relationship to serum igf-1 and gh levels. |
2012-09-21 |
2023-08-12 |
human |
| Paul M Stewart, Mark Sherloc. Mortality and pituitary disease. Annales d'endocrinologie. vol 73. issue 2. 2012-09-14. PMID:22503666. |
control of cortisol secretion and growth hormone (gh) hypersecretion (together with cardiovascular risk factor reduction) is key in the normalisation of mortality rates in patients with cushing's disease and acromegaly, respectively, though some excess mortality may persist even in "cured" patients. |
2012-09-14 |
2023-08-12 |
Not clear |
| Eui Hyun Kim, Min Chul Oh, Eun Jig Lee, Sun Ho Ki. Predicting long-term remission by measuring immediate postoperative growth hormone levels and oral glucose tolerance test in acromegaly. Neurosurgery. vol 70. issue 5. 2012-09-13. PMID:22067418. |
the suppression of the growth hormone (gh) on an oral glucose tolerance test (ogtt) has been accepted as the most reliable parameter for determining remission of acromegaly. |
2012-09-13 |
2023-08-12 |
Not clear |